MeV-IN-1

MeV-IN-1 (20-30 h) specifically inhibits the replication of live MV-Edm in Vero/HeLa cells, with an IC₅₀ of approximately 55 μM, and induces only negligible cytotoxicity even at concentrations as high as 600 μM^[1].
MeV-IN-1 (30 h) inhibits measles virus glycoprotein-mediated membrane fusion in transfected cells, with an IC₅₀ of approximately 100 μM^[1].
MeV-IN-1 (300 μM; 1 h-30 h) does not interfere with the adhesion of MV-Edm to Vero/HeLa cells, but inhibits the post-adhesion entry process of the virus by targeting membrane fusion^[1].
MeV-IN-1 (300 μM; 30 min) inhibits membrane lipid fusion induced by measles virus (MV) glycoproteins in transfected cells, but has no effect on lipid fusion mediated by SV5^[1].
MeV-IN-1 (0-600 μM) exhibits mutation-specific activity against measles virus (MV) recombinants in Vero/HeLa cells, with enhanced potency against MV-F^V94M, MV-F^V94L and MV-F^V94I, reduced potency against MV-F^V94A, and high resistance observed for MV-F^V94G, which confirms that the cavity of the F protein is its target site^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.